Register Login

EMERGENT BIOSOLUTIONS INC. (EBS)

SymbolEBS
NameEMERGENT BIOSOLUTIONS INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address400 PROFESSIONAL DRIVE,SUITE 400, GAITHERSBURG, Maryland, 20879, United States
Telephone+1 240 631-3200
Fax—
Email—
Websitehttps://www.emergentbiosolutions.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001367644
Description

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

Additional info from NASDAQ:
Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

2026-05-04 21:30

Director Dayal Sujata Tyagi 🟡 adjusted position in 22.9K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $8.94 Transaction Date: Apr 30, 2026 | Filing ID: 000004

Read more
2026-05-04 21:30

Director DeGolyer Donald W 🟡 adjusted position in 21.2K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $8.96 Transaction Date: Apr 30, 2026 | Filing ID: 000004

Read more
2026-05-04 21:29

Director Katkin Keith 🟡 adjusted position in 21.2K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $8.28 Transaction Date: Apr 30, 2026 | Filing ID: 000002

Read more
2026-05-04 21:29

Director White Marvin L 🟢 acquired 36.6K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $7.99 Transaction Date: Apr 30, 2026 | Filing ID: 000002

Read more
2026-05-04 21:29

Director FOWLER JOHN D JR 🟢 acquired 36.6K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $7.99 Transaction Date: Apr 30, 2026 | Filing ID: 000012

Read more
2026-05-04 21:28

Director Richard Ronald 🟢 acquired 36.6K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $7.99 Transaction Date: Apr 30, 2026 | Filing ID: 000004

Read more
2026-05-04 21:28

Director Zoon Kathryn C 🟡 adjusted position in 19.4K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $8.97 Transaction Date: Apr 30, 2026 | Filing ID: 000003

Read more
2026-05-04 21:27

Director Fowler Neal Franklin 🟢 acquired 36.6K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $7.99 Transaction Date: Apr 30, 2026 | Filing ID: 000003

Read more
2026-05-04 21:23

Director Harsanyi Zsolt 🟢 acquired 36.6K shares (1 derivative) of Emergent BioSolutions Inc. (EBS) at $7.99 Transaction Date: Apr 30, 2026 | Filing ID: 000005

Read more
2026-05-01 20:30

Williams Paul Anthony 🟢 acquired 100.1K shares of Emergent BioSolutions Inc. (EBS) Transaction Date: Apr 29, 2026 | Filing ID: 000017

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07268612 Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for… — Anthrax Not_Yet_Recruiting 2035-11-01 2037-11-01 ClinicalTrials.gov
NCT03569553 A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in I… — Inhalational Anthrax Not_Yet_Recruiting 2027-05-30 2027-07-01 ClinicalTrials.gov
NCT07478471 Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax — Infections, Bacterial Not_Yet_Recruiting 2027-05-01 2030-12-01 ClinicalTrials.gov
NCT02177721 Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalat… Phase4 Infections, Bacterial Not_Yet_Recruiting 2027-01-01 2035-12-01 ClinicalTrials.gov
NCT03569514 Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®… — Anthrax Not_Yet_Recruiting 2026-11-30 2027-08-01 ClinicalTrials.gov
NCT05935917 Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets… Phase1 Smallpox Completed 2023-05-30 2023-09-27 ClinicalTrials.gov
NCT05349617 Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years Phase3 Chikungunya Virus Completed 2022-05-12 2023-08-08 ClinicalTrials.gov
NCT05377255 Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in He… Phase1 Opioid Overdose Completed 2022-03-28 2022-05-10 ClinicalTrials.gov
NCT05194358 Study of SIAN Nasal Spray in Healthy Adults Phase1 Cyanide Poisoning Completed 2021-12-21 2023-10-13 ClinicalTrials.gov
NCT05142306 A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM… Phase1 SARS-CoV-2 Infection Completed 2021-12-07 2022-05-31 ClinicalTrials.gov
NCT05155319 Universal Influenza A Vaccine in Healthy Adults Phase1 Human Influenza Completed 2021-12-01 2023-10-10 ClinicalTrials.gov
NCT05065983 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus V… Phase2 Chikungunya Virus Completed 2021-10-11 2022-05-05 ClinicalTrials.gov
NCT05072080 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccin… Phase3 Chikungunya Virus Completed 2021-09-29 2023-04-03 ClinicalTrials.gov
NCT04661839 A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Adminis… Phase1 COVID-19 Completed 2020-12-24 2021-07-27 ClinicalTrials.gov
NCT03992872 Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vac… Phase2 Chikungunya Completed 2019-11-20 2021-01-19 ClinicalTrials.gov
NCT04067011 Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study Phase2 Anthrax Completed 2019-08-12 2020-03-19 ClinicalTrials.gov
NCT03877926 VELOCITY: An Anthrax Vaccine Clinical Study Phase3 Anthrax Completed 2019-03-11 2020-08-06 ClinicalTrials.gov
NCT03624946 Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Viru… Phase1 Zika Virus Infection Completed 2018-06-27 2019-03-06 ClinicalTrials.gov
NCT03483961 Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase2 Chikungunya Virus Infection Completed 2018-04-18 2020-09-21 ClinicalTrials.gov
NCT03425149 Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenic… Phase1 Zika Virus Completed 2018-02-24 2018-11-16 ClinicalTrials.gov
NCT03315104 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenou… Phase2 Influenza A H3N2 Completed 2017-11-17 2019-06-17 ClinicalTrials.gov
NCT03220737 VAXCHORA Pediatric Study to Assess Safety and Immunogenicity Phase4 Cholera (Disorder) Completed 2017-07-21 2020-03-06 ClinicalTrials.gov
NCT03160339 A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 Phase1 Adenoviral Infection Terminated 2017-05-01 2017-11-27 ClinicalTrials.gov
NCT02696291 Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple A… Phase1 Viral Infection Terminated 2016-05-27 2017-03-02 ClinicalTrials.gov
NCT02443623 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Phase4 Smallpox Vaccine Adverse Reaction Completed 2015-09-01 2021-08-01 ClinicalTrials.gov
NCT02391909 Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among… — Typhoid Fever Completed 2015-08-26 2017-02-21 ClinicalTrials.gov
NCT02771730 Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healt… Phase1 Healthy Volunteer Terminated 2015-03-01 2017-02-01 ClinicalTrials.gov
NCT02339155 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed Phase4 Infections, Bacterial Completed 2015-02-24 2017-06-06 ClinicalTrials.gov
NCT02055183 BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients … — Botulism Completed 2014-10-01 2017-07-01 ClinicalTrials.gov
NCT02051062 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Phase4 Botulism Enrolling_By_Invitation 2014-10-01 2028-07-31 ClinicalTrials.gov
NCT02061358 Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solut… Phase1 Viral Infection Completed 2014-07-01 2015-09-01 ClinicalTrials.gov
NCT02145377 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Phase2 Cholera Completed 2014-07-01 2015-03-01 ClinicalTrials.gov
NCT02094586 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 i… Phase3 Cholera Completed 2014-05-01 2015-06-01 ClinicalTrials.gov
NCT02100631 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase3 Cholera Completed 2014-05-01 2015-06-01 ClinicalTrials.gov
NCT01989533 Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers Phase1 Vaccine Response Completed 2013-11-19 2019-04-08 ClinicalTrials.gov
NCT01979406 A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adeno… Phase1 Anthrax Infection Completed 2013-11-01 2015-09-01 ClinicalTrials.gov
NCT01895855 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX… Phase3 Cholera Completed 2013-09-01 2014-11-01 ClinicalTrials.gov
NCT01770743 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedu… Phase2 Anthrax Completed 2013-01-01 2014-12-01 ClinicalTrials.gov
NCT01753115 Ciprofloxacin BioThrax Co-Administration Study Phase2 Anthrax Completed 2012-12-01 2013-08-01 ClinicalTrials.gov
NCT01683773 Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A Phase1 Tuberculosis Completed 2012-09-01 2014-08-01 ClinicalTrials.gov
NCT01653392 BioThrax® (Anthrax) Vaccine in Pregnancy Registry — Pregnancy Complications Completed 2012-07-01 2020-02-01 ClinicalTrials.gov
NCT01585181 Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Phase1 Cholera Completed 2012-04-01 2013-01-01 ClinicalTrials.gov
NCT01491607 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Expo… Phase3 Anthrax Completed 2011-11-01 2012-05-01 ClinicalTrials.gov
NCT01395082 ACAM2000® Myopericarditis Registry — Myocarditis Completed 2011-04-01 2019-02-04 ClinicalTrials.gov
NCT01263691 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Heal… Phase1 Bacillus Anthracis (Anthrax) Infection Completed 2010-12-01 2012-06-01 ClinicalTrials.gov
NCT01158157 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV Phase3 Smallpox Vaccine Adverse Reaction Completed 2010-09-13 2012-02-14 ClinicalTrials.gov
NCT01202695 Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) Phase1 Anthrax Completed 2010-08-01 2011-06-01 ClinicalTrials.gov
NCT01006798 Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccin… Phase1 Bird Flu Completed 2009-10-01 2011-09-01 ClinicalTrials.gov
NCT01540929 Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military… — Smallpox Completed 2009-09-01 2012-09-01 ClinicalTrials.gov
NCT01311674 Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Im… Phase3 Healthy Volunteers Terminated 2009-09-01 2011-03-11 ClinicalTrials.gov
NCT00845650 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Phase1 Anthrax Completed 2009-02-01 2010-10-01 ClinicalTrials.gov
NCT00928577 Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) — Smallpox Completed 2008-12-01 2015-12-01 ClinicalTrials.gov
NCT00927719 Safety Surveillance Study of ACAM2000® Vaccinia Vaccine — Smallpox Completed 2008-12-01 2017-12-31 ClinicalTrials.gov
NCT00679172 Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate … Phase2 Typhoid Completed 2008-05-01 2008-12-01 ClinicalTrials.gov
NCT00634933 Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis Phase2 Arthritis, Rheumatoid Terminated 2008-03-01 2012-10-01 ClinicalTrials.gov
NCT00639678 A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subje… Phase3 Healthy Completed 2008-03-01 2008-09-01 ClinicalTrials.gov
NCT00636519 Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the… Phase1 Healthy Volunteers Completed 2008-02-01 2009-10-01 ClinicalTrials.gov
NCT02016963 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of… Phase2 Therapeutic Treatment of Inhalation Anthrax Completed 2008-01-31 2008-05-31 ClinicalTrials.gov
NCT01374984 VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complicatio… — Complication of Smallpox Vaccination Enrolling_By_Invitation 2007-08-01 2027-08-01 ClinicalTrials.gov
NCT00448253 Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human … Phase1 Symptoms of Inhalational Anthrax Completed 2007-07-01 2008-09-01 ClinicalTrials.gov
NCT00893516 CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Phase2 T-cell Lymphoma Terminated 2007-05-01 2008-12-01 ClinicalTrials.gov
NCT00360737 Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses Phase1 Healthy Completed 2006-07-01 2010-04-01 ClinicalTrials.gov
NCT00877656 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Phase2 T Cell Lymphoma Completed 2005-08-01 2008-12-01 ClinicalTrials.gov
NCT00053495 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Withou… Phase2 Smallpox Completed 2003-01-01 2003-11-01 ClinicalTrials.gov
NCT00053482 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Phase2 Smallpox Completed 2003-01-01 2003-10-01 ClinicalTrials.gov
Total clinical trials: 65
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT03877926
AV7909 Other Phase PHASE3 Anthrax COMPLETED NCT03877926
Placebo Other Phase PHASE1 Zika Virus Infection COMPLETED NCT03624946
Zika Virus Immune Globulin (ZIKV-IG) Other Phase PHASE1 Zika Virus Infection COMPLETED NCT03624946
Placebo Other Phase PHASE1 Human Influenza COMPLETED NCT05155319
UFluA 60 µg each antigen/dose Other Phase PHASE1 Human Influenza COMPLETED NCT05155319
UFluA 20 µg each antigen/dose Other Phase PHASE1 Human Influenza COMPLETED NCT05155319
Prednisone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Methylprednisolone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
TRU-015 Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Prednisone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Methylprednisolone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
TRU-015 Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Prednisone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Methylprednisolone Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
TRU-015 Other Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
MVA85A Other Phase PHASE1 Tuberculosis COMPLETED NCT01683773
AERAS-402 Other Phase PHASE1 Tuberculosis COMPLETED NCT01683773
Raxibacumab Other Phase PHASE2 Therapeutic Treatment of Inhalation Anthrax COMPLETED NCT02016963
Placebo Other Phase PHASE1 Zika Virus COMPLETED NCT03425149
VLA1601 Other Phase PHASE1 Zika Virus COMPLETED NCT03425149
Shanchol Other Phase PHASE2 Cholera COMPLETED NCT02145377
Placebo Other Phase PHASE2 Cholera COMPLETED NCT02145377
PXVX0200 10E9 Other Phase PHASE2 Cholera COMPLETED NCT02145377
PXVX0200 10E8 Other Phase PHASE2 Cholera COMPLETED NCT02145377
gp 120 Protein Boost Other Phase PHASE1 Vaccine Response COMPLETED NCT01989533
Ad4-EnvC150 Other Phase PHASE1 Vaccine Response COMPLETED NCT01989533
Ad4-mgag Other Phase PHASE1 Vaccine Response COMPLETED NCT01989533
Placebo Other Phase PHASE1 Cholera COMPLETED NCT01585181
PXVX0200 Other Phase PHASE1 Cholera COMPLETED NCT01585181
Placebo Other Phase PHASE4 Cholera (Disorder) COMPLETED NCT03220737
VAXCHORA (Cholera Vaccine, Live, Oral) Other Phase PHASE4 Cholera (Disorder) COMPLETED NCT03220737
Placebo Other Phase PHASE3 Cholera COMPLETED NCT02100631
PXVX0200 Other Phase PHASE3 Cholera COMPLETED NCT02100631
Placebo Other Phase PHASE3 Cholera COMPLETED NCT02094586
PXVX0200 Lot C Other Phase PHASE3 Cholera COMPLETED NCT02094586
PXVX0200 Lot B Other Phase PHASE3 Cholera COMPLETED NCT02094586
PXVX0200 Lot A Other Phase PHASE3 Cholera COMPLETED NCT02094586
placebo Other Phase PHASE3 Cholera COMPLETED NCT01895855
PXVX0200 Other Phase PHASE3 Cholera COMPLETED NCT01895855
CHIKV VLP, adjuvanted Other Phase PHASE2 Chikungunya Virus COMPLETED NCT05065983
Placebo Other Phase PHASE2 Chikungunya Virus Infection COMPLETED NCT03483961
CHIKV VLP/adjuvanted Other Phase PHASE2 Chikungunya Virus Infection COMPLETED NCT03483961
CHIKV VLP/unadjuvanted Other Phase PHASE2 Chikungunya Virus Infection COMPLETED NCT03483961
Vivotif Other Preclinical Typhoid Fever COMPLETED NCT02391909
BAT Other Preclinical Botulism COMPLETED NCT02055183
Observational Intervention Other Preclinical Pregnancy Complications COMPLETED NCT01653392
Placebo Other Phase PHASE1 Anthrax COMPLETED NCT01202695
AVP-21D9 Other Phase PHASE1 Anthrax COMPLETED NCT01202695
Placebo for FLU-IGIV Other Phase PHASE2 Influenza A H3N2 COMPLETED NCT03315104
FLU-IGIV Other Phase PHASE2 Influenza A H3N2 COMPLETED NCT03315104
Teva Ad4/Ad7 Vaccine Other Phase PHASE1 Adenoviral Infection TERMINATED NCT03160339
PXVX0047 Vaccine Other Phase PHASE1 Adenoviral Infection TERMINATED NCT03160339
AIDSVAX B/E Other Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Placebo Comparator Other Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Ad4-EnvC150 Other Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Ad4-mgag Other Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Placebo Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B Y mg (dose to be determined) oral solution Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B X mg (dose to be determined) oral solution Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 150 mg oral solution Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 75 mg oral solution Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 30 mg oral solution Other Phase PHASE1 Viral Infection TERMINATED NCT02696291
Vaccination with ACAM2000 Other Phase PHASE4 Smallpox Vaccine Adverse Reaction COMPLETED NCT02443623
Diphenhydramine Other Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
Raxibacumab Other Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
AVA Other Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
Placebo Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 1000 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 720 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 360 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 180 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 90 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 30 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 10 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 3 mg Other Phase PHASE1 Viral Infection COMPLETED NCT02061358
Ad4-PA-GPI-1 Other Phase PHASE1 Anthrax Infection COMPLETED NCT01979406
Ad4-PA-1 Other Phase PHASE1 Anthrax Infection COMPLETED NCT01979406
AVA Other Phase PHASE1 Anthrax Infection COMPLETED NCT01979406
BioThrax Other Phase PHASE2 Anthrax COMPLETED NCT01770743
AV7909 Other Phase PHASE2 Anthrax COMPLETED NCT01770743
hepatitis B vaccine Other Phase PHASE3 Healthy Volunteers TERMINATED NCT01311674
Control Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 4 Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 3 Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 2 Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 1 Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
BioThrax Other Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
ACAM2000 Other Phase PHASE3 Smallpox Vaccine Adverse Reaction COMPLETED NCT01158157
Sanofi Pasteur Influenza Virus Vaccine, H5N1 Other Phase PHASE1 Bird Flu COMPLETED NCT01006798
Ad4-H5-Vtn Other Phase PHASE1 Bird Flu COMPLETED NCT01006798
Placebo Other Phase PHASE1 Bird Flu COMPLETED NCT01006798
BioThrax Other Phase PHASE3 Anthrax COMPLETED NCT01491607
Placebo Other Phase PHASE3 Chikungunya Virus COMPLETED NCT05072080
CHIKV VLP/adjuvant Other Phase PHASE3 Chikungunya Virus COMPLETED NCT05072080
Chikungunya Other Phase PHASE2 Chikungunya COMPLETED NCT03992872
Placebo Other Phase PHASE3 Chikungunya Virus COMPLETED NCT05349617
CHIKV VLP/adjuvant Other Phase PHASE3 Chikungunya Virus COMPLETED NCT05349617
Brincidofovir Other Phase PHASE1 Smallpox COMPLETED NCT05935917
Stabilized Isoamyl Nitrite (SIAN) Other Phase PHASE1 Cyanide Poisoning COMPLETED NCT05194358
COVID-HIG Other Phase PHASE1 SARS-CoV-2 Infection COMPLETED NCT05142306
Placebo (saline) Other Phase PHASE1 COVID-19 COMPLETED NCT04661839
COVID-HIGIV Other Phase PHASE1 COVID-19 COMPLETED NCT04661839
Ciprofloxacin Other Phase PHASE2 Anthrax COMPLETED NCT01753115
BioThrax Other Phase PHASE2 Anthrax COMPLETED NCT01753115
AV7909 Other Phase PHASE2 Anthrax COMPLETED NCT04067011
Doxycycline 100Mg Tablet Other Phase PHASE2 Anthrax COMPLETED NCT04067011
Ciprofloxacin 500Mg Tablet Other Phase PHASE2 Anthrax COMPLETED NCT04067011
VIGIV Other Preclinical Complication of Smallpox Vaccination ENROLLING_BY_INVITATION NCT01374984
Blood sample collection Other Phase PHASE4 Botulism ENROLLING_BY_INVITATION NCT02051062
8 mg naloxone NARCAN Nasal Spray Other Phase PHASE1 Opioid Overdose COMPLETED NCT05377255
16 mg naloxone AP003 Other Phase PHASE1 Opioid Overdose COMPLETED NCT05377255
Collection of samples BIOLOGICAL Preclinical Infections, Bacterial NOT_YET_RECRUITING NCT07478471
CYFENDUS BIOLOGICAL Preclinical Anthrax NOT_YET_RECRUITING NCT07268612
Brincidofovir DRUG Phase PHASE1 Smallpox COMPLETED NCT05935917
Stabilized Isoamyl Nitrite (SIAN) DRUG Phase PHASE1 Cyanide Poisoning COMPLETED NCT05194358
UFluA 60 µg each antigen/dose BIOLOGICAL Phase PHASE1 Human Influenza COMPLETED NCT05155319
UFluA 20 µg each antigen/dose BIOLOGICAL Phase PHASE1 Human Influenza COMPLETED NCT05155319
COVID-HIG BIOLOGICAL Phase PHASE1 SARS-CoV-2 Infection COMPLETED NCT05142306
CHIKV VLP/adjuvant BIOLOGICAL Phase PHASE3 Chikungunya Virus COMPLETED NCT05349617
CHIKV VLP, adjuvanted BIOLOGICAL Phase PHASE2 Chikungunya Virus COMPLETED NCT05065983
Placebo (saline) OTHER Phase PHASE1 COVID-19 COMPLETED NCT04661839
COVID-HIGIV BIOLOGICAL Phase PHASE1 COVID-19 COMPLETED NCT04661839
Doxycycline 100Mg Tablet DRUG Phase PHASE2 Anthrax COMPLETED NCT04067011
Ciprofloxacin 500Mg Tablet DRUG Phase PHASE2 Anthrax COMPLETED NCT04067011
Chikungunya BIOLOGICAL Phase PHASE2 Chikungunya COMPLETED NCT03992872
Zika Virus Immune Globulin (ZIKV-IG) BIOLOGICAL Phase PHASE1 Zika Virus Infection COMPLETED NCT03624946
AIGIV DRUG Preclinical Inhalational Anthrax NOT_YET_RECRUITING NCT03569553
CHIKV VLP/adjuvanted BIOLOGICAL Phase PHASE2 Chikungunya Virus Infection COMPLETED NCT03483961
CHIKV VLP/unadjuvanted BIOLOGICAL Phase PHASE2 Chikungunya Virus Infection COMPLETED NCT03483961
VLA1601 BIOLOGICAL Phase PHASE1 Zika Virus COMPLETED NCT03425149
Placebo for FLU-IGIV OTHER Phase PHASE2 Influenza A H3N2 COMPLETED NCT03315104
FLU-IGIV BIOLOGICAL Phase PHASE2 Influenza A H3N2 COMPLETED NCT03315104
VAXCHORA (Cholera Vaccine, Live, Oral) BIOLOGICAL Phase PHASE4 Cholera (Disorder) COMPLETED NCT03220737
Teva Ad4/Ad7 Vaccine BIOLOGICAL Phase PHASE1 Adenoviral Infection TERMINATED NCT03160339
PXVX0047 Vaccine BIOLOGICAL Phase PHASE1 Adenoviral Infection TERMINATED NCT03160339
AIDSVAX B/E BIOLOGICAL Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Placebo Comparator OTHER Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
UV-4B Y mg (dose to be determined) oral solution DRUG Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B X mg (dose to be determined) oral solution DRUG Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 150 mg oral solution DRUG Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 75 mg oral solution DRUG Phase PHASE1 Viral Infection TERMINATED NCT02696291
UV-4B 30 mg oral solution DRUG Phase PHASE1 Viral Infection TERMINATED NCT02696291
Vaccination with ACAM2000 BIOLOGICAL Phase PHASE4 Smallpox Vaccine Adverse Reaction COMPLETED NCT02443623
Vivotif BIOLOGICAL Preclinical Typhoid Fever COMPLETED NCT02391909
Diphenhydramine DRUG Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
Sample Collection BIOLOGICAL Phase PHASE4 Infections, Bacterial NOT_YET_RECRUITING NCT02177721
Shanchol BIOLOGICAL Phase PHASE2 Cholera COMPLETED NCT02145377
PXVX0200 10E9 BIOLOGICAL Phase PHASE2 Cholera COMPLETED NCT02145377
PXVX0200 10E8 BIOLOGICAL Phase PHASE2 Cholera COMPLETED NCT02145377
PXVX0200 Lot C BIOLOGICAL Phase PHASE3 Cholera COMPLETED NCT02094586
PXVX0200 Lot B BIOLOGICAL Phase PHASE3 Cholera COMPLETED NCT02094586
PXVX0200 Lot A BIOLOGICAL Phase PHASE3 Cholera COMPLETED NCT02094586
UV-4B 1000 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 720 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 360 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 180 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 90 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 30 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 10 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
UV-4B 3 mg DRUG Phase PHASE1 Viral Infection COMPLETED NCT02061358
BAT DRUG Preclinical Botulism COMPLETED NCT02055183
Blood sample collection BIOLOGICAL Phase PHASE4 Botulism ENROLLING_BY_INVITATION NCT02051062
Raxibacumab BIOLOGICAL Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
gp 120 Protein Boost BIOLOGICAL Phase PHASE1 Vaccine Response COMPLETED NCT01989533
Ad4-EnvC150 BIOLOGICAL Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Ad4-mgag BIOLOGICAL Phase PHASE1 Healthy Volunteer TERMINATED NCT02771730
Ad4-PA-GPI-1 BIOLOGICAL Phase PHASE1 Anthrax Infection COMPLETED NCT01979406
Ad4-PA-1 BIOLOGICAL Phase PHASE1 Anthrax Infection COMPLETED NCT01979406
AVA BIOLOGICAL Phase PHASE4 Infections, Bacterial COMPLETED NCT02339155
AV7909 BIOLOGICAL Phase PHASE2 Anthrax COMPLETED NCT04067011
Ciprofloxacin DRUG Phase PHASE2 Anthrax COMPLETED NCT01753115
MVA85A BIOLOGICAL Phase PHASE1 Tuberculosis COMPLETED NCT01683773
AERAS-402 BIOLOGICAL Phase PHASE1 Tuberculosis COMPLETED NCT01683773
Observational Intervention BIOLOGICAL Preclinical Pregnancy Complications COMPLETED NCT01653392
PXVX0200 BIOLOGICAL Phase PHASE3 Cholera COMPLETED NCT02100631
VIGIV BIOLOGICAL Preclinical Complication of Smallpox Vaccination ENROLLING_BY_INVITATION NCT01374984
hepatitis B vaccine BIOLOGICAL Phase PHASE3 Healthy Volunteers TERMINATED NCT01311674
Control DRUG Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 4 BIOLOGICAL Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 3 BIOLOGICAL Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 2 BIOLOGICAL Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
AV7909 Formulation 1 BIOLOGICAL Phase PHASE1 Bacillus Anthracis (Anthrax) Infection COMPLETED NCT01263691
BioThrax BIOLOGICAL Phase PHASE3 Anthrax COMPLETED NCT03877926
AVP-21D9 DRUG Phase PHASE1 Anthrax COMPLETED NCT01202695
ACAM2000 BIOLOGICAL Phase PHASE3 Smallpox Vaccine Adverse Reaction COMPLETED NCT01158157
Sanofi Pasteur Influenza Virus Vaccine, H5N1 BIOLOGICAL Phase PHASE1 Bird Flu COMPLETED NCT01006798
Ad4-H5-Vtn BIOLOGICAL Phase PHASE1 Bird Flu COMPLETED NCT01006798
Placebo BIOLOGICAL Phase PHASE3 Chikungunya Virus COMPLETED NCT05349617
ACAM2000® smallpox vaccine BIOLOGICAL Preclinical Smallpox COMPLETED NCT00927719
CHOP DRUG Phase PHASE2 T-cell Lymphoma TERMINATED NCT00893516
CHOP + CD4 BIOLOGICAL Phase PHASE2 T-cell Lymphoma TERMINATED NCT00893516
HuMax-CD4 BIOLOGICAL Phase PHASE2 T Cell Lymphoma COMPLETED NCT00877656
Gamunex 360 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
AIGIV 14.0 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
Gamunex 180 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
AIGIV 7.0 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
Gamunex 90 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
AIGIV 3.5 mg/kg BIOLOGICAL Phase PHASE1 Anthrax COMPLETED NCT00845650
Placebo (Cohorts 1-4 pooled) OTHER Phase PHASE2 Typhoid COMPLETED NCT00679172
Dose of of 1.7 x 10^10 CFU (Cohort 4) BIOLOGICAL Phase PHASE2 Typhoid COMPLETED NCT00679172
Dose of 1.1 x 10^10 CFU (Cohort 3) BIOLOGICAL Phase PHASE2 Typhoid COMPLETED NCT00679172
Dose of 7.5 x 10^9 CFU (Cohort 2) BIOLOGICAL Phase PHASE2 Typhoid COMPLETED NCT00679172
Dose of 5.0 x 10^9 CFU (Cohort 1) BIOLOGICAL Phase PHASE2 Typhoid COMPLETED NCT00679172
raxibacumab DRUG Phase PHASE3 Healthy COMPLETED NCT00639678
placebo BIOLOGICAL Phase PHASE3 Cholera COMPLETED NCT01895855
Botulism Antitoxin Heptavalent (Equine) Types A-G BIOLOGICAL Phase PHASE1 Healthy Volunteers COMPLETED NCT00636519
Botulism Antitoxin Bivalent (Equine) Types A and B BIOLOGICAL Phase PHASE1 Healthy Volunteers COMPLETED NCT00636519
Prednisone DRUG Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
Methylprednisolone DRUG Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
TRU-015 DRUG Phase PHASE2 Arthritis, Rheumatoid TERMINATED NCT00634933
NP-015 BIOLOGICAL Phase PHASE1 Symptoms of Inhalational Anthrax COMPLETED NCT00448253
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) BIOLOGICAL Phase PHASE1 Healthy COMPLETED NCT00360737
vaccinia virus (calf lymph): Dryvax BIOLOGICAL Phase PHASE2 Smallpox COMPLETED NCT00053495
Vaccinia virus: ACAM2000 smallpox vaccine BIOLOGICAL Phase PHASE2 Smallpox COMPLETED NCT00053495
Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® BIOLOGICAL Phase PHASE2 Smallpox COMPLETED NCT00053482
ACAM2000 Smallpox Vaccine BIOLOGICAL Phase PHASE2 Smallpox COMPLETED NCT00053482
Total products: 233